Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility multicenter study

Not Applicable

• Conditions: (1) breast cancer with histological confirmation; (2) stage II or III breast cancer and previous standard anthracycline and/or taxane-based PSC, followed by curative surgery; (3) age 20-75 years; (4) Eastern Cooperative Oncology Group performance status 0,1; (5) adequate gastrointestinal function; (6) adequate organ function

• Registration Number: JPRN-UMIN000013469
• Lead Sponsor: Saitama Medical University International Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-03-20
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

Patients with serious complications, a history of drug hypersensitivity, brain metastases with any symptoms, active secondary cancer, or pregnant women

Study & Design

• Study Type: Interventional,observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint was the percentage of the scheduled adjuvant chemotherapy completed using S-1 calculated by the Kaplan Meier method.